Safety and Efficacy of Reduced-Dose Versus Full-Dose Alteplase for Acute Pulmonary Embolism: A Multicenter Observational Comparative Effectiveness Study

Author:

Melamed Roman1,Tierney David M.23,Xia Ranran4,Brown Caitlin S.45,Mara Kristin C.6,Lillyblad Matthew7,Sidebottom Abbey8,Wiley Brandon M.9,Khapov Ivan10,Gajic Ognjen11

Affiliation:

1. Department of Critical Care, Abbott Northwestern Hospital, Allina Health, Minneapolis, MN.

2. Department of Graduate Medical Education, Abbott Northwestern Hospital, Allina Health, Minneapolis, MN.

3. Department of Medicine, Abbott Northwestern Hospital, Allina Health, Minneapolis, MN.

4. Department of Pharmacy, Mayo Clinic, Rochester, MN.

5. Department of Emergency Medicine, Mayo Clinic, Rochester, MN.

6. Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN.

7. Department of Pharmacy, Abbott Northwestern Hospital, Allina Health, Minneapolis, MN.

8. Department of Care Delivery Research, Allina Health, Minneapolis, MN.

9. Department of Medicine, Los Angeles General Medical Center, Keck School of Medicine, University of Southern California, Los Angeles, CA.

10. Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN.

11. Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN.

Abstract

Objectives: Systemic thrombolysis improves outcomes in patients with pulmonary embolism (PE) but is associated with the risk of hemorrhage. The data on efficacy and safety of reduced-dose alteplase are limited. The study objective was to compare the characteristics, outcomes, and complications of patients with PE treated with full- or reduced-dose alteplase regimens. Design: Multicenter retrospective observational study. Setting: Tertiary care hospital and 15 community and academic centers of a large healthcare system. Patients: Hospitalized patients with PE treated with systemic alteplase. Interventions: None. Measurements and Main Results: Pre- and post-alteplase hemodynamic and respiratory variables, patient outcomes, and complications were compared. Propensity score (PS) weighting was used to adjust for imbalances of baseline characteristics between reduced- and full-dose patients. Separate analyses were performed using the unweighted and weighted cohorts. Ninety-eight patients were treated with full-dose (100 mg) and 186 with reduced-dose (50 mg) regimens. Following alteplase, significant improvements in shock index, blood pressure, heart rate, respiratory rate, and supplemental oxygen requirements were observed in both groups. Hemorrhagic complications were lower with the reduced-dose compared with the full-dose regimen (13% vs. 24.5%, p = 0.014), and most were minor. Major extracranial hemorrhage occurred in 1.1% versus 6.1%, respectively (p = 0.022). Complications were associated with supratherapeutic levels of heparin anticoagulation in 37.5% of cases and invasive procedures in 31.3% of cases. The differences in complications persisted after PS weighting (15.4% vs. 24.7%, p = 0.12 and 1.3% vs. 7.1%, p = 0.067), but did not reach statistical significance. There were no significant differences in mortality, discharge destination, ICU or hospital length of stay, or readmission after PS weighting. Conclusions: In a retrospective, PS-weighted observational study, when compared with the full-dose, reduced-dose alteplase results in similar outcomes but fewer hemorrhagic complications. Avoidance of excessive levels of anticoagulation or invasive procedures should be considered to further reduce complications.

Funder

Mayo Midwest Pharmacy Research Committee

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Critical Care and Intensive Care Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3